Om

PolyPeptide Group AG is a specialized contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients. PolyPeptide Group AG develops and manufactures synthetic peptides and related intermediates for pharmaceutical and biotech customers, supporting projects from pre-clinical and clinical development through commercial production. Its services span custom peptide synthesis, process development, analytical support, and GMP manufacturing, with applications in therapeutic areas such as metabolic diseases and other drug programs. The company operates a global network of GMP-certified facilities in Europe, the United States, and India, giving it a broad manufacturing footprint and close proximity to customers across major life-science markets. Headquartered in Baar, Switzerland, PolyPeptide Group AG plays an important role in the supply chain for modern peptide therapeutics, helping bring specialized API products to regulated healthcare markets worldwide.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I POLYPEPTIDE GROUP MED ENDAVU: Køb PolyPeptide Group ($PPGNE) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i PolyPeptide Group, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.